Opportunities for Nano-Formulations in Type 2 Diabetes Mellitus Treatments

E-ISSN： 1873-4316|16|10|853-870

ISSN： 1389-2010

Source： Current Pharmaceutical Biotechnology, Vol.16, Iss.10, 2015-01, pp. : 853-870

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Linagliptin: In Type 2 Diabetes Mellitus

By Scott Lesley J.

Drugs, Vol. 71, Iss. 5, 2011-03 ,pp. : 611-624

Adis International

Access to resources Recommend Favorite

The prevention of type 2 diabetes mellitus

By Davies Melanie J.

Clinical Medicine, Vol. 3, Iss. 5, 2003-09 ,pp. : 470-474

Royal College Of Physicians

Access to resources Recommend Favorite

Lixisenatide for type 2 diabetes mellitus

By Christensen Mikkel Knop Filip K Vilsbøøll Tina Holst Jens J

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 4, 2011-04 ,pp. : 549-557

Informa Healthcare

Access to resources Recommend Favorite

Vitamins and Type 2 Diabetes Mellitus

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 15, Iss. 1, 2015-03 ,pp. : 54-63

Bentham Science Publishers

Access to resources Recommend Favorite

Effect of various treatments on leptin, adiponectin, ghrelin and neuropeptide Y in patients with type 2 diabetes mellitus

By Katsiki Niki Mikhailidis Dimitri P Gotzamani-Psarrakou Anna Yovos John G Karamitsos Dimitrios

Expert Opinion on Therapeutic Targets, Vol. 15, Iss. 4, 2011-04 ,pp. : 401-420

Informa Healthcare

Access to resources Recommend Favorite